Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
AI/ML Innovations Inc. (AIML) is a publicly traded technology company focused on the development and commercialization of artificial intelligence (AI) and machine learning (ML) solutions, primarily in the healthcare and life sciences sectors. The company positions itself as an applied AI platform company, emphasizing clinical decision support, data analytics, and software tools intended to improve diagnostic accuracy, operational efficiency, and patient outcomes. Available public disclosures indicate that AIML’s strategy centers on acquiring, developing, and scaling AI-driven technologies with near-term commercialization potential.
The company traces its origins to earlier technology and data-driven business models before rebranding and restructuring to focus specifically on AI and ML applications. This evolution included a shift away from generalized data or digital engagement platforms toward regulated, healthcare-oriented AI solutions. Public filings and investor materials consistently describe AIML as pursuing a portfolio-based approach, combining internal development with acquisitions to accelerate market entry. Some historical details and early operational milestones vary slightly across disclosures; where discrepancies exist, data is inconclusive based on available public sources.
Business Operations
AIML’s operations are organized around several AI-enabled software and analytics businesses, with revenue generation primarily expected from licensing, subscription-based software, and commercialization of clinical decision-support tools. The company’s reported operating focus includes healthcare AI platforms, clinical analytics, and machine learning models designed for use by healthcare providers, researchers, and institutional partners. Commercial revenue remains limited relative to development-stage activity, based on recent public financial disclosures.
Key operating subsidiaries and business units include NeuroDoc, Tech2Health, and AI Rx, each addressing different aspects of healthcare AI, such as diagnostic support, patient data analysis, and applied machine learning research. AIML operates mainly through wholly owned subsidiaries rather than large-scale joint ventures, and it relies on a combination of proprietary algorithms, licensed technologies, and clinical data partnerships. International operations exist primarily through subsidiaries and research collaborations rather than large physical infrastructure.
Strategic Position & Investments
Strategically, AIML emphasizes growth through targeted acquisitions and internal development of AI assets that can be validated in regulated healthcare environments. The company has publicly disclosed acquisitions intended to strengthen its intellectual property portfolio and accelerate entry into clinical and pharmaceutical markets, including the acquisition of NeuroDoc and Tech2Health, which form the core of its healthcare AI strategy.
AIML’s investment focus includes emerging applications of AI in clinical decision support, drug development analytics, and precision medicine. The company positions itself as an integrator of applied AI rather than a foundational model developer, seeking to bridge academic research and commercial healthcare deployment. While management has articulated ambitions for scalable healthcare impact, public filings indicate that many initiatives remain in development or early commercialization stages.
Geographic Footprint
The company is headquartered in Canada, with its principal executive offices located in British Columbia. AIML’s operational footprint extends into North America and parts of Europe, primarily through subsidiaries, research collaborations, and customer engagements rather than large standalone international offices.
AIML reports market activity and strategic relationships across Canada, the United States, and select European jurisdictions, reflecting the global nature of healthcare AI research and commercialization. International exposure is largely investment- and partnership-driven, and the company does not currently report significant region-specific revenue concentration based on publicly available filings.
Leadership & Governance
AIML is led by an executive team with experience spanning technology development, healthcare innovation, and public company management. Governance is overseen by a board of directors responsible for strategic direction, capital allocation, and regulatory compliance. Public disclosures emphasize a leadership philosophy centered on disciplined acquisition, scientific validation, and long-term value creation in regulated markets.
Key executives include:
- Tim Daniels – Chief Executive Officer
- Paul Duffy – Executive Chairman
- Andy Green – Chief Financial Officer
- Dr. Joe Geraci – Chief Scientific Officer
Management has consistently communicated a strategic vision focused on building a diversified portfolio of clinically relevant AI technologies while maintaining capital efficiency. Certain executive roles and historical leadership changes vary slightly across reporting periods; where inconsistencies exist, data is inconclusive based on available public sources.